摘要
目的:评价吡柔比星膀胱内灌注预防浅表性膀胱癌术后复发的有效性及安全性。方法:符合入选标准的患者于手术后2周内开始行吡柔比星膀胱灌注,每次30mg,每周1次共8次,以后每月1次共1年,定期膀胱镜检查进行随访。结果:132例浅表性膀胱移行细胞癌患者,术后平均随访时间12.2±5.74个月。肿瘤复发22例,总复发率16.7%。其中复发性肿瘤的复发率明显高于初发肿瘤(P=0.003),而不同肿瘤分期、分级及单发与多发肿瘤患者间的复发率未见明显差异。不良反应主要为尿路刺激症状和尿常规异常。结论:吡柔比星膀胱灌注预防浅表性膀胱癌术后复发的效果明确,疗效满意,患者耐受性好,是较为理想的膀胱灌注化疗药物。
Objective： To evaluate the efficacy and safety of intravesical instillation of pirarubicin （THP） for preventing postoperative recurrence of superficial bladder cancer. Methods： Patients with superficial transitional cell bladder cancer who were suitable for inclusion criteria were enrolled in this study. THP （30 mg/50 ml of normal saline） was instilled intravesically within two weeks after operation once a week for eight weeks, followed by oncea month till one year. Regular cystoscopy was performed for the follow-up. Results： All the patients were followed up for an average time of 12.2±5.74 months. Tumor recurrence was found in 22 cases and the total recurrence rate was 16.7%. There was a significant difference in the recurrence rate between primary and recurring tumor （P=-0.003）, but no difference of recurrence rate was found between different tumor grades, tumor staging and tumor number. Urinary irritation and abnormal urine analysis were the predominant adverse reactions. Conclusion： Intravesical administration of THP after operation was effective and well-tolerated for preventing tumor recurrence.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2005年第21期1245-1247,共3页
Chinese Journal of Clinical Oncology
关键词
吡柔比星
膀胱癌
膀胱灌注
Pirarubicin Bladder Cancer Intravesical Instillation
